Literature DB >> 27230017

Derivatives of biarylalkyl carboxylic acid induce pleiotropic phenotypes in adult Schistosoma mansoni in vitro.

Ariane S Blohm1, Patrick Mäder2, Thomas Quack1, Zhigang Lu1, Steffen Hahnel1, Martin Schlitzer2, Christoph G Grevelding3.   

Abstract

Schistosomes and other parasitic platyhelminths cause infectious diseases of worldwide significance for humans and animals. Despite their medical and economic importance, vaccines are not available and the number of drugs is alarmingly limited. For most platyhelminths including schistosomes, Praziquantel (PZQ) is the commonly used drug. With respect to its regular application in mass treatment programs, however, there is increasing concern about resistance development.Previous studies demonstrated that inhibitors used to treat non-parasitic human diseases may be useful to be tested for their effects on parasites. To this end, we focused on biarylalkyl carboxylic acids (BACAs) as basis, which had been shown before to be interesting candidates in the context of finding alternative approaches to treat diabetes mellitus. We tested 32 chemically modified derivatives of these substances (biarylalkyl carboxylic acid derivatives (BACADs)) for their effects on adult Schistosoma mansoni in vitro. Treatment with 18 BACADs resulted in egg production-associated phenotypes and reduced pairing stability. In addition, 12 of these derivatives affected vitality and/or caused severe tegument damage, gut dilatation, or other forms of tissue disintegration which led to the death of worms. In most cases (10/12), one derivative caused more than one phenotype at a time. In vitro experiments in the presence of serum albumin (SA) and alpha-acidic glycoprotein (AGP) indicated a varying influence of these blood components on the effects of two selected derivatives. The variety of observed phenotypes suggested that different targets were hit. The results demonstrated that BACADs are interesting substances with respect to their anti-schistosomal effects.

Entities:  

Keywords:  Biarylalkyl carboxylic acid; Drug development; In vitro culture; Platyhelminths; Schistosoma mansoni; Serum component

Mesh:

Substances:

Year:  2016        PMID: 27230017     DOI: 10.1007/s00436-016-5146-7

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  50 in total

1.  Schistosomula, pre-adults and adults of Schistosoma mansoni ingest fluorescence-labelled albumin in vitro and in vivo: implication for a drug-targeting model.

Authors:  M C Holtfreter; M Loebermann; E Frei; D Riebold; D Wolff; G Hartung; R Kinzelbach; E C Reisinger
Journal:  Parasitology       Date:  2010-05-26       Impact factor: 3.234

Review 2.  Schistosomiasis control: praziquantel forever?

Authors:  Donato Cioli; Livia Pica-Mattoccia; Annalisa Basso; Alessandra Guidi
Journal:  Mol Biochem Parasitol       Date:  2014-06-21       Impact factor: 1.759

Review 3.  The social and economic context and determinants of schistosomiasis japonica.

Authors:  Yi-Xin Huang; Lenore Manderson
Journal:  Acta Trop       Date:  2005-10-03       Impact factor: 3.112

4.  Characterization of the cGMP-dependent protein kinase SmcGK1 of Schistosoma mansoni.

Authors:  Silke Leutner; Svenja Beckmann; Christoph G Grevelding
Journal:  An Acad Bras Cienc       Date:  2011-06       Impact factor: 1.753

5.  Selective binding of imatinib to the genetic variants of human alpha1-acid glycoprotein.

Authors:  Ilona Fitos; Júlia Visy; Ferenc Zsila; György Mády; Miklós Simonyi
Journal:  Biochim Biophys Acta       Date:  2006-08-25

6.  Praziquantel resistance.

Authors:  Sanaa S Botros; James L Bennett
Journal:  Expert Opin Drug Discov       Date:  2007-10       Impact factor: 6.098

7.  Novel inhibitors and substrates of bilirubin: UDP-glucuronosyltransferase. Arylalkylcarboxylic acids.

Authors:  S Fournel-Gigleux; S R Shepherd; M C Carre; B Burchell; G Siest; P Caubere
Journal:  Eur J Biochem       Date:  1989-08-15

Review 8.  The relationship between water, sanitation and schistosomiasis: a systematic review and meta-analysis.

Authors:  Jack E T Grimes; David Croll; Wendy E Harrison; Jürg Utzinger; Matthew C Freeman; Michael R Templeton
Journal:  PLoS Negl Trop Dis       Date:  2014-12-04

Review 9.  Schistosome ABC multidrug transporters: From pharmacology to physiology.

Authors:  Robert M Greenberg
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2014-09-26       Impact factor: 4.077

10.  A cluster-randomised intervention trial against Schistosoma japonicum in the Peoples' Republic of China: bovine and human transmission.

Authors:  Darren J Gray; Gail M Williams; Yuesheng Li; Honggen Chen; Simon J Forsyth; Robert S Li; Adrian G Barnett; Jiagang Guo; Allen G Ross; Zheng Feng; Donald P McManus
Journal:  PLoS One       Date:  2009-06-12       Impact factor: 3.240

View more
  3 in total

Review 1.  Chemotherapy for human schistosomiasis: how far have we come? What's new? Where do we go from here?

Authors:  Godwin Akpeko Dziwornu; Henrietta Dede Attram; Samuel Gachuhi; Kelly Chibale
Journal:  RSC Med Chem       Date:  2020-04-06

2.  Discovery by organism based high-throughput screening of new multi-stage compounds affecting Schistosoma mansoni viability, egg formation and production.

Authors:  Alessandra Guidi; Cristiana Lalli; Roberto Gimmelli; Emanuela Nizi; Matteo Andreini; Nadia Gennari; Fulvio Saccoccia; Steven Harper; Alberto Bresciani; Giovina Ruberti
Journal:  PLoS Negl Trop Dis       Date:  2017-10-06

3.  The anti-fecundity effect of 5-azacytidine (5-AzaC) on Schistosoma mansoni is linked to dis-regulated transcription, translation and stem cell activities.

Authors:  Kathrin K Geyer; Sabrina E Munshi; Martin Vickers; Michael Squance; Toby J Wilkinson; Daniel Berrar; Cristian Chaparro; Martin T Swain; Karl F Hoffmann
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2018-04-01       Impact factor: 4.077

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.